{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:53:05Z","timestamp":1768884785959,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":3129,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/ajt.12714","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T13:58:38Z","timestamp":1397483918000},"page":"994-1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: \u201cA Flood of Opportunity\u201d"],"prefix":"10.1016","volume":"14","author":[{"given":"E.J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.12714_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/ajt.12714_bib2","unstructured":"World Health Organization. Available at: www.who.int. Accessed September 1, 2012."},{"key":"10.1111\/ajt.12714_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1111\/ajt.12714_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"Prevalence of HCV infection in the United States","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/ajt.12714_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.22165","article-title":"Changing trends in HCV-related mortality in USA","volume":"47","author":"Wise","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2004.07.020","article-title":"HCV and increasing incidence of hepatocellular carcinoma: A population-based study","volume":"127","author":"Davila","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in United States","volume":"9","author":"Davis","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hep.21347","article-title":"Global challenges in liver disease","volume":"44","author":"Williams","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1111\/ajt.12714_bib10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C kinetics during and immediately after transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/jlts.2002.30141","article-title":"Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCV-infected liver","volume":"8","author":"Ballardini","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1111\/ajt.12714_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/gast.1996.v110.pm8536853","article-title":"A longitudinal analysis of hepatitis C virus replication following liver transplantation","volume":"110","author":"Gane","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"Association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib14","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on HCV recurrence after liver transplantation: A randomised-controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(94)90759-5","article-title":"Quantitation of HCV RNA in liver transplant recipients","volume":"106","author":"Chazouilleres","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510290412","article-title":"Recurrent and new HCV infection after liver transplantation","volume":"29","author":"Everhart","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0016-5085(99)70352-5","article-title":"Association of multispecific CD4+ response to HCV and severity of recurrence after liver transplantation","volume":"117","author":"Rosen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/lt.20300","article-title":"Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation","volume":"10","author":"Gruener","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MCG.0b013e31825833be","article-title":"Peginterferon-\u03b1-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation","volume":"46","author":"Gordon","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/ajt.12714_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients in recurrent HCV","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.04.022","article-title":"Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFN-2a plus ribavirin","volume":"57","author":"Calmus","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/lt.21760","article-title":"Predictors of SVR after antiviral treatment for HCV recurrence following liver transplantation","volume":"15","author":"Cescon","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.24074","article-title":"IL28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with HCV infection","volume":"53","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","article-title":"Variants in IL28B in liver recipients and doors correlate with response to PEG\/RBV therapy for recurrent hepatitis C","volume":"139","author":"Fukuhara","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/lt.22271","article-title":"PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus","volume":"17","author":"Bzowej","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJM199603283341302","article-title":"Long-term outcome of hepatitis C infection after liver transplantation","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.510290122","article-title":"High incidence of allograft cirrhosis in HCV genotype 1b following transplantation","volume":"29","author":"Prieto","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/lt.20238","article-title":"One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection","volume":"10","author":"Firpi","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation","volume":"43","author":"Blasco","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10620-009-0981-3","article-title":"The use of cyclosporine for recurrent hepatitis C after liver transplant: A randomized pilot study","volume":"55","author":"Firpi","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1111\/ajt.12714_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/TP.0b013e318223d836","article-title":"Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large, multicenter cohort study","volume":"92","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12714_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lt.20532","article-title":"Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation","volume":"12","author":"Firpi","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lt.23516","article-title":"Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: A systematic review and meta-analysis","volume":"19","author":"Rabie","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib35","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib37","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib39","first-page":"1092A","article-title":"Efficacy and safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotics according to the age. Data from the CUPIC cohort (ANRS CO20)","volume":"58","author":"Hezode","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib40","first-page":"218A","article-title":"High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV infected patients awaiting liver-transplantation","volume":"56","author":"Verna","year":"2012","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1111\/ajt.12714_bib42","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(13)60025-2","article-title":"A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: Report from the CRUSH-C group","volume":"58","author":"Verna","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib43","first-page":"431","article-title":"P239-III telaprevir can be used safely with concomitant tacrolimus in the post transplant setting","volume":"12","author":"Rogers","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib44","first-page":"188","article-title":"Initial experience with telaprevir for treating hepatitis C virus in liver recipients: Virologic response, safety and tolerability","volume":"12","author":"Burton","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib45","first-page":"430","article-title":"Post liver transplant therapy with telaprevir for recurrent hepatitis C","volume":"12","author":"de Oliveira Pereira","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib46","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S0168-8278(12)60215-3","article-title":"Use of telaprevir plus PEG interferon\/ribavirin for null responders post OLT with advanced fibrosis\/cholestatic hepatitis C","volume":"56","author":"Kwo","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib47","first-page":"430","article-title":"P234-III initial experience utilising telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation","volume":"12","author":"Pungpapong","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib49","unstructured":"An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE). Available at: Clinicaltrials.gov: NCT01571583. Accessed November 20, 2012."},{"key":"10.1111\/ajt.12714_bib50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib51","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1016\/S0168-8278(11)61365-2","article-title":"VX-22 with TVR alone or in combination with PEG-IFN and RBV in treatment naive patients with chronic HCV GT-1: ZENITH study interim results","volume":"54","author":"Di Bisceglie","year":"2011","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib52","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"12 Week IFN-free regimen of ABT-450\/r + ABT-333 + RBV achieved SVR12 in more than 90% of treatment na\u00efve HCV GT-1 infected subjects and in 47% of previous nonresponders","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib53","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(13)60005-7","article-title":"Safety and efficacy of IFN-free regimen of ABT-450\/r, ABT-267 and ABT-333 +\/\u2212 RBV in patients with chronic HCV GT-1 infection","volume":"58","author":"Kowdley","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib54","doi-asserted-by":"crossref","first-page":"S573","DOI":"10.1016\/S0168-8278(13)61422-1","article-title":"Interim analysis of IFN-free and RBV-free regimen of daclatasvir, asunaprevir and BMS-791325 in treatment-naive HCV GT-1 infected patients","volume":"58","author":"Everson","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib55","unstructured":"FDA approves sovaldi for chronic hepatitis C. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm377888.htm. Accessed December 6, 2013."},{"key":"10.1111\/ajt.12714_bib56","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib57","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib58","first-page":"733A","article-title":"Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: The VALENCE trial","volume":"58","author":"Zeuzem","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib59","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/S0168-8278(13)61416-6","article-title":"Sustained virologic response with daclatasvir plus sofosbuvir \u00b1 ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC)","volume":"58","author":"Sulkowski","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib60","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B nonnucleoside inhibitor GS-9669 for hepatitis C genotype 1","volume":"146","author":"Gane","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12714_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Once daily PSI-7977 plus RBV: Pegylated interferon-alfa not required for sustained virologic response in treatment-na\u00efve patients with HCV GT2 or GT3","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib63","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib64","first-page":"732A","article-title":"Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation","volume":"58","author":"Forns","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib65","first-page":"LB2","article-title":"Sofosbuvir and RBV for the treatment of established recurrent HCV infection after liver transplantation: Preliminary results of a prospective, multicenter study","volume":"58","author":"Charlton","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib66","unstructured":"A Phase 2, multicenter, open-label study to investigate the safety and efficacy of sofosbuvir\/ledipasvir fixed-dose combination + ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant. Available at: Clinicaltrials.gov: NCT01938430. Accessed November 20, 2012."},{"key":"10.1111\/ajt.12714_bib67","unstructured":"Open-label, single arm, Phase 2 study to evaluate the safety and efficacy of the combination of ABT-450\/ritonavir\/ABT-267 (ABT-450\/r\/ABT-267) and ABT-333 coadministered with ribavirin (RBV) in adult liver transplant recipients with genotype 1 hepatitis C virus (HCV) infection. Available at: Clinicaltrials.gov: NCT01782495. Accessed November 20, 2012."},{"key":"10.1111\/ajt.12714_bib68","unstructured":"Phase 2, Open-label study to investigate the pharmacokinetics, efficacy, safety, and tolerability of the combination of simeprevir (TMC435), daclatasvir (BMS-790052) and ribavirin (RBV) in subjects with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation. Available at: Clinicaltrials.gov: NCT01938625. Accessed December 15, 2012."},{"key":"10.1111\/ajt.12714_bib69","first-page":"314A","article-title":"Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation","volume":"58","author":"Curry","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/ajt.12714_bib71","unstructured":"A Phase 2, multicenter, open-label, randomized study to investigate the safety and efficacy of GS-7977 and ribavirin administered for 48 weeks in patients infected with chronic HCV with cirrhosis and portal hypertension with or without liver decompensation. Available at: Clinicaltrials.gov: NCT01687257. Accessed August 10, 2012."},{"key":"10.1111\/ajt.12714_bib72","first-page":"S653","article-title":"Impact of highly effective antiviral therapy on burden of hepatocellular carcinoma in hepatitis C cirrhosis","volume":"58","author":"Kim","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib73","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12714_bib74","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0168-8278(13)60045-8","article-title":"Long-term tenofovir therapy and the risk of hepatocellular carcinoma","volume":"58","author":"Kim","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib75","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.transproceed.2003.10.083","article-title":"Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation","volume":"35","author":"Mukherjee","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.12714_bib76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/lt.20074","article-title":"Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C","volume":"10","author":"Abdelmalek","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib77","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lt.20189","article-title":"Effects of interferon on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation","volume":"10","author":"Stravitz","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/ajt.12714_bib78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent HCV infection after liver transplantation with combination Peg-IFN alpha 2b and ribavirin","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12714_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2005.02.015","article-title":"Combined treatment with pegylated interferon and ribavirin in the acute phase of HCV recurrence after liver transplantation","volume":"43","author":"Castells","year":"2005","journal-title":"J Hepatol"},{"key":"10.1111\/ajt.12714_bib80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2005.03795.x","article-title":"Pegylated versus standard interferon-alfa in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy","volume":"20","author":"Toniutto","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/ajt.12714_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1155\/2005\/745197","article-title":"Peg-IFN alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation","volume":"19","author":"Babatin","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/ajt.12714_bib82","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib83","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12714_bib84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2362.2008.01958.x","article-title":"Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection","volume":"38","author":"Reiberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/ajt.12714_bib85","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/lt.21707","article-title":"Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"15","author":"Berenguer","year":"2009","journal-title":"Liver Transpl"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.12714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522254379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522254379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:04:12Z","timestamp":1761627852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522254379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1600613522254379"],"URL":"https:\/\/doi.org\/10.1111\/ajt.12714","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: \u201cA Flood of Opportunity\u201d","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.12714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}